ストックスクリーナーアプリを入手
1.72
1.15%
-0.02
アフターアワーズ：
1.72
前日終値:
$1.74
開ける：
$1.73
24時間の取引高:
457.83K
Relative Volume:
0.63
時価総額：
$47.48M
収益：
$80.97M
当期純損益:
$-78.31M
株価収益率:
-0.1158
EPS:
-14.85
ネットキャッシュフロー:
$-129.56M
1週間 パフォーマンス:
-11.34%
1か月 パフォーマンス:
+9.55%
6か月 パフォーマンス:
+0.58%
1年 パフォーマンス:
-27.12%
1日の値動き範囲:
$1.72
$1.81
1週間の範囲:
$1.72
$1.99
52週間の値動き範囲:
$1.355
$4.43
Fortress Biotech Inc Stock (FBIO) Company Profile
名前
Fortress Biotech Inc
セクター
電話
781-652-4500
住所
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
FBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
1.72 | 47.48M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-15 | 再開されました | ROTH MKM | Buy |
| 2022-08-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-02 | 開始されました | The Benchmark Company | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2018-02-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
| 2017-03-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-10-03 | 開始されました | ROTH Capital | Buy |
すべてを表示
Fortress Biotech Inc (FBIO) 最新ニュース
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK
Objective long/short (FBIOP) Report - Stock Traders Daily
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan
Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.52 (As of Dec. 04, 2024) - GuruFocus.com
Fortress Biotech (STU:CNB1) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech (STU:CNB1) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World
FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com
(FBIOP) Trading Signals - Stock Traders Daily
Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com
Certain Restricted Stock Units of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com
Fortress Biotech (FRA:CNB1) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024) - GuruFocus.com
Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks
Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks
Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fortress Biotech: Q3 Earnings Snapshot - mySA
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks
Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan
Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Where are the Opportunities in (FBIOP) - Stock Traders Daily
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewswire
How To Trade (FBIOP) - Stock Traders Daily
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St
Fortress Biotech Inc (FBIO) 財務データ
収益
当期純利益
現金流量
EPS
Fortress Biotech Inc (FBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 11 '24 |
Buy |
7.48 |
5,000 |
37,418 |
127,500 |
| Jin David | Chief Financial Officer |
Jul 10 '24 |
Buy |
7.50 |
500 |
3,750 |
500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 09 '24 |
Buy |
7.39 |
5,000 |
36,971 |
122,500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jul 08 '24 |
Buy |
7.35 |
5,000 |
36,764 |
117,500 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jun 28 '24 |
Buy |
1.64 |
20,000 |
32,724 |
2,893,905 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
May 16 '24 |
Buy |
1.76 |
10,000 |
17,589 |
2,873,905 |
| Klein Dov | Director |
May 20 '24 |
Sale |
1.89 |
10,000 |
18,900 |
53,400 |
| ROSENWALD LINDSAY A MD | President, CEO & Chairman |
Jan 05 '24 |
Buy |
2.38 |
50,000 |
118,770 |
2,863,905 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):